var data={"title":"Lucinactant (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lucinactant (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/499050?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lucinactant-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lucinactant (United States: Not available): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22626021\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Surfaxin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13855977\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Lung Surfactant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292498\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lucinactant-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lucinactant (United States: Not available): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Respiratory distress syndrome (prophylaxis):</b> Premature Infants: Endotracheal: 5.8 mL/kg birth weight; may repeat for up to 3 subsequent doses (total of 4 doses) may be administered at &ge;6-hour intervals within the first 48 hours of life; guidelines suggest that dosing intervals more frequent than every 12 hours should not be necessary unless surfactant is being inactivated by an infectious process, meconium, or blood (AAP [Polin 2014]). <b>Note:</b> For newborns who do not require mechanical ventilation for severe RDS, current guidelines recommend using CPAP immediately after birth with subsequent selective surfactant administration (AAP [Polin 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317805\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317806\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25497899\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intratracheal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Surfaxin: 30 mg/mL (8.5 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292483\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292499\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>For endotracheal administration only.</b> Prior to administration, verify that the suspension has been properly warmed, followed by vigorous shaking until the suspension is uniform, free-flowing, and opaque white to off-white.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Slowly draw up the appropriate amount of lucinactant into a single, appropriately sized syringe (depending on total dose volume) using a 16- or 18-gauge needle. Neonate may be suctioned prior to administration; allow neonate to stabilize prior to administration. Administer endotracheally by instillation through a 5-French end-hole catheter inserted into the infant's endotracheal tube with infant properly positioned.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer in four aliquots of 1.45 mL/kg each (<sup>1</sup>/<sub>4</sub> of total volume) alternating positions between right and left lateral decubitus. Each aliquot is instilled as a bolus with continued positive pressure ventilation; evaluate neonate's respiratory status and allow for stabilization between aliquots; oxygen saturation and heart rate should be &ge;90% and &gt;120 bpm, respectively, prior to administering the next aliquot. Following administration of one full dose (four aliquots), withhold suctioning for 1 hour unless signs of significant airway obstruction occur and keep the head of the neonate&rsquo;s bed elevated &ge;10&deg; for at least 1 to 2 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13855979\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Respiratory distress syndrome</b>: Prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292487\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following events were observed during the dosing procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Endotracheal tube reflux (18% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Oxygen desaturation (8% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Obstruction of endotracheal tube (6% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Cardiovascular: Bradycardia (3% to 5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292484\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the FDA-approved labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292485\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transient adverse effects: Transient episodes of bradycardia, decreased oxygen saturation, endotracheal tube blockage, or reflux of lucinactant into endotracheal tube may occur. Interrupt dosing procedure and initiate measures to stabilize infant's condition; may reinstitute after the patient is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For endotracheal administration only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inappropriate use: In clinical trials of lucinactant in adults with acute respiratory distress syndrome (ARDS), an increased incidence of sepsis, pneumothorax, pulmonary embolism, hypotension, sepsis, and death was observed; therapy is not appropriate in the treatment of ARDS in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395095\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395093\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83330&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292501\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Continuous heart rate and transcutaneous O<sub>2</sub> saturation; ventilator settings; frequent ABG sampling is necessary to prevent postdosing hyperoxia and hypocarbia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292494\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Surfactant administration replaces deficient or ineffective endogenous lung surfactant in neonates at risk of developing RDS. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces. Lucinactant, a synthetic surfactant containing phospholipids, also contains sinapultide (KL4 peptide) which resembles and is believed to mimic the action of one of the human surfactant proteins (SPs), namely SP-B. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25745801\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Surfaxin Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/mL (8.5 mL): $1032.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Moya FR, Gadzinowski J, Bancalari E, et al, &ldquo;A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants,&rdquo; <i>Pediatrics</i>, 2005, 115(4):1018-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lucinactant-united-states-not-available-drug-information/abstract-text/15805380/pubmed\" target=\"_blank\" id=\"15805380\">15805380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moya FR, Sinha S, Gadzinowski J, et al, &ldquo;One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials,&rdquo; <i>Pediatrics</i>, 2007, 119(6): e1361-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lucinactant-united-states-not-available-drug-information/abstract-text/17533176/pubmed\" target=\"_blank\" id=\"17533176\">17533176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polin RA, Carlo WA; Committee on Fetus and Newborn; American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. <i>Pediatrics</i>. 2014;133(1):156-163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lucinactant-united-states-not-available-drug-information/abstract-text/24379227/pubmed\" target=\"_blank\" id=\"24379227\">24379227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al, &ldquo;A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome,&rdquo; <i>Pediatrics</i>, 2005, 115(4):1030-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lucinactant-united-states-not-available-drug-information/abstract-text/15805381/pubmed\" target=\"_blank\" id=\"15805381\">15805381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surfaxin (lucinactant) [prescribing information]. Warrington, PA: Discovery Laboratories; October 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lucinactant-united-states-not-available-drug-information/abstract-text/15805381/pubmed\" target=\"_blank\" id=\"15805381\">15805381</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83330 Version 46.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F22626021\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13855977\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F14292498\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16317805\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16317806\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F25497899\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14292483\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14292499\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13855979\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14292487\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14292484\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14292485\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14395095\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14395093\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14292501\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14292494\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F25745801\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83330|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lucinactant-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">Lucinactant (United States: Not available): Pediatric drug information</a></li></ul></div></div>","javascript":null}